Acyl-CoA synthetase bubblegum family member 1 (ACSBG1)

ACSBG1 (Acyl-CoA synthetase bubblegum family member 1) is an enzyme belonging to the acyl-CoA synthetase family, responsible for the activation (conversion to CoA esters) of long-chain and very long-chain fatty acids, thus linking fatty acid uptake and metabolism to cellular lipid synthesis and mitochondrial beta-oxidation[1][2][5]. Highly expressed in the brain and certain steroidogenic tissues, ACSBG1 plays a pivotal role in myelin synthesis and neuronal function and is necessary for normal fatty acid metabolic homeostasis[1][4][6]. Deficiency or dysfunction of ACSBG1 has been implicated in neurodegenerative disease, myelination disorders, and immune dysregulation, notably influencing the differentiation of CD4+ T cell subtypes (Th17 and Treg), with potential ties to inflammatory disease such as colitis[3][6]. There are currently no approved drugs directly targeting ACSBG1, but its central role in lipid metabolism and links to disease biology make it a molecule of emerging biomedical interest[2][5][6].

Other names

BG1BGMGR-LACSLPDhBG1hsBGFLJ30320MGC14352lipidosinbubblegumvery long-chain acyl-CoA synthetaseKIAA0631

Not directly targeted by approved drugs; mechanistic approaches would include inhibition or modulation of fatty acid-CoA ligase activity, impacting fatty acid metabolism and downstream effects on lipid synthesis, myelin stability, or immune cell function